


**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

**LISTING OF CLAIMS:**

1. (currently amended): A galactosamine derivative compound represented by the following formula (1):



wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>5</sub> each independently represents SO<sub>3</sub><sup>-</sup> or H, and at least one of them represents SO<sub>3</sub><sup>-</sup>;

R<sub>3</sub> represents H, acetyl or SO<sub>3</sub><sup>-</sup>;

R<sub>4</sub> represents H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted acyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group;

X represents O, S, NH or CH<sub>2</sub>; and

~~~~~ represents an α bond or a β bond, and

with the proviso that a compound in which R<sub>1</sub> and R<sub>2</sub> are H, R<sub>5</sub> is SO<sub>3</sub><sup>-</sup>, R<sub>3</sub> is an acetyl group, R<sub>4</sub> is a para-nitrophenyl group and X is O, and a compound in which R<sub>1</sub>, R<sub>2</sub>, and R<sub>5</sub> are each independently SO<sub>3</sub><sup>-</sup> or H, R<sub>3</sub> is H, an acetyl group or SO<sub>3</sub><sup>-</sup>, R<sub>4</sub> is a benzyl group and X is O, are excluded.

2. (currently amended): The galactosamine derivative compound according to claim 1, wherein R<sub>1</sub> and R<sub>2</sub> each is H; R<sub>3</sub> is an acetyl group; R<sub>4</sub> is a substituted or unsubstituted aryl group; and R<sub>5</sub> is SO<sub>3</sub><sup>-</sup>, with the proviso that a compound wherein R<sub>4</sub> is a para-nitrophenyl group is excluded.

3. (currently amended): The galactosamine derivative compound according to claim 1, wherein R<sub>1</sub> is SO<sub>3</sub><sup>-</sup>; R<sub>2</sub> and R<sub>5</sub> each is H; R<sub>3</sub> is an acetyl group; and R<sub>4</sub> is a substituted or unsubstituted aryl group.

4. (currently amended): The galactosamine derivative compound according to claim 1, wherein R<sub>1</sub> and R<sub>5</sub> each is H; R<sub>2</sub> is SO<sub>3</sub><sup>-</sup>; R<sub>3</sub> is an acetyl group; and R<sub>4</sub> is a substituted or unsubstituted aryl group.

5.-6. (canceled).

7. (withdrawn-currently amended): A method for inhibiting activity of a sulfotransferase, which comprises allowing the galactosamine derivative compound according to claim 1 to be present in an enzyme reaction system of the sulfotransferase.

8.-9. (canceled).

10. (withdrawn-currently amended): A medicament based on inhibition of sulfotransferase activity, which comprises the galactosamine derivative compound according to claim 1 as an active ingredient.

11. (withdrawn-currently amended): A medicament for treating or preventing diseases caused by acceleration of sulfotransferase activity, which comprises the galactosamine derivative compound according to claim 1 as an active ingredient.

12. (withdrawn-currently amended): A method for treating or preventing diseases caused by acceleration of sulfotransferase activity, which comprises administering to a subject in need thereof an effective amount of the galactosamine derivative compound according to claim 1.